Beneficial Ownership Report · SCHEDULE 13G/A
Aura Biosciences, Inc.
AURANASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Aura Biosciences, Inc.
- Company CIK
- 0001501796
- Street
- 80 Guest Street
- City
- Boston
- State / country code
- MA
- Postal code
- 02135
Statement details
- Amendment number
- 2
- Security class
- Common Stock, par value $0.00001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Montanova Capital, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Group designation
- b
- Aggregate amount owned
- 2,973,971.00
- Percent of class
- 2.9
- Sole voting power
- 0.00
- Shared voting power
- 2,973,971.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,973,971.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Averill Master Fund, Ltd.
- Citizenship / organization
- E9
- Reporting person type
- CO
- Group designation
- b
- Aggregate amount owned
- 2,535,780.00
- Percent of class
- 2.4
- Sole voting power
- 0.00
- Shared voting power
- 2,535,780.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,535,780.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Aaron Cowen
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Group designation
- b
- Aggregate amount owned
- 2,973,971.00
- Percent of class
- 2.9
- Sole voting power
- 0.00
- Shared voting power
- 2,973,971.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,973,971.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Aura Biosciences, Inc.
Principal executive office address
80 Guest Street, Boston, MA 02135
Item 2
Citizenship
Montanova Capital, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
Filing person
Items 6 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by Averill Master Fund, Ltd. (the "Fund"), which may be deemed to be indirectly beneficially owned by Montanova Capital, LLC and Aaron Cowen, as well as Common Stock that may be acquired upon the exercise of pre-funded warrants with no expiration date with an exercise price of $0.00001 per share of Common Stock ("Pre-Funded Warrants"), subject to the limitations on exercise described below. The Pre-Funded Warrants are only exercisable to the extent that after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the outstanding Common Stock (the "Maximum Percentage"). By written notice to the Issuer, the Fund may from time to time increase or decrease the Maximum Percentage applicable to it to any other percentage not in excess of 19.99%, provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer. As a result of this restriction, the Pre-Funded Warrants are not all presently exercisable and the number of shares of Common Stock that may be issued upon exercise of the Pre-Funded Warrants by the above holders may change depending upon changes in the outstanding Common Stock. Montanova Capital, LLC Averill Master Fund, Ltd. Aaron Cowen
Principal business or residence address
Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America
Item 3
Not applicable indication
Y
Item 4
Percent of class
Montanova Capital, LLC - 2.9% Averill Master Fund, Ltd. - 2.4% Aaron Cowen - 2.9%
Amount beneficially owned
Montanova Capital, LLC - 2,973,971 Averill Master Fund, Ltd. - 2,535,780 Aaron Cowen - 2,973,971
Sole voting power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Shared voting power
Montanova Capital, LLC - 2,973,971 Averill Master Fund, Ltd. - 2,535,780 Aaron Cowen - 2,973,971
Sole dispositive power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Shared dispositive power
Montanova Capital, LLC - 2,973,971 Averill Master Fund, Ltd. - 2,535,780 Aaron Cowen - 2,973,971
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Montanova Capital, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, par value $0.00001 per share.
Item 7
Not applicable indication
N
Subsidiaries
Please see Exhibit B attached hereto.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification
Signature comments
* Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Signature 1
- Reporting person
- Montanova Capital, LLC
- Signed
- /s/ Andrew Nathanson
- Title
- Andrew Nathanson, General Counsel and Chief Compliance Officer
- Date
- 11/13/2026
Signature 2
- Reporting person
- Averill Master Fund, Ltd.
- Signed
- /s/ Andrew Nathanson
- Title
- Andrew Nathanson, Authorized Signatory
- Date
- 11/13/2026
Signature 3
- Reporting person
- Aaron Cowen
- Signed
- /s/ Aaron Cowen
- Title
- Aaron Cowen
- Date
- 11/13/2026
Filed exhibits
Company context
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class front-line vision-preserving therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.